News

Welcome to the future of translational and early clinical development.
Scientifically driven with access to multiple centres of excellence.
Customisable full service underpinned by the highest quality clinical conduct.
World-leading patient and healthy volunteer recruitment capabilities.
Delivering the best value solution for early clinical development.
The CRO has published a Review article discussing the current knowledge on Long-COVID and the efforts by the pharmaceutical industry, medical device companies as well as academic research to develop efficient and safe medicines to prevent or treat Long-COVID.
As of 7th June 2023 the World Health Organization reported over 767 million confirmed cases of COVID-19. Although most people recover from COVID-19 within a few weeks, about 10% of them develop a complex of long-lasting disabling symptoms called Long-COVID beyond 6 months from infection. Thus, more than 76 million individuals are currently affected worldwide by Long-COVID conditions expected to result in a significant global health and socioeconomic burden.
In this Review article we discuss the current knowledge on Long-COVID including the symptom complex, predictors and supposed pathogenic mechanisms. We describe how the pharmaceutical industry, medical device companies as well as academic research, including the Charité Universitätsmedizin Berlin and Charité Research Organisation GmbH, are now increasing their efforts to develop efficient and safe medicines/therapeutic interventions to treat this burdensome disease.
Get in touch with our Business Development Team to find out how Charité Research Organisation can deliver optimal value for your early clinical research projects and help you reach Proof of Concept faster.
Studienberatung
Patienten und Probanden erreichen uns unter (030) 450 539 210.
Please feel free to discuss your early clinical trials with us. Your message will be received attentively by our business development team. We come back to you with feedback from our clinicians and project management experts....
Some more text